234 related articles for article (PubMed ID: 28843356)
1. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set.
Ma C; Panaccione R; Fedorak RN; Parker CE; Nguyen TM; Khanna R; Siegel CA; Peyrin-Biroulet L; D'Haens G; Sandborn WJ; Feagan BG; Jairath V
Clin Gastroenterol Hepatol; 2018 May; 16(5):637-647.e13. PubMed ID: 28843356
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review.
Ma C; Hussein IM; Al-Abbar YJ; Panaccione R; Fedorak RN; Parker CE; Nguyen TM; Khanna R; Siegel CA; Peyrin-Biroulet L; Pai RK; Vande Casteele N; D'Haens GR; Sandborn WJ; Feagan BG; Jairath V
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1407-1419.e22. PubMed ID: 29596987
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review.
Ma C; van Rhijn BD; Jairath V; Nguyen TM; Parker CE; Aceves SS; Furuta GT; Gupta SK; Katzka DA; Safroneeva E; Schoepfer AM; Straumann A; Spergel JM; Pai RK; Feagan BG; Hirano I; Dellon ES; Bredenoord AJ
Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1714-1729.e3. PubMed ID: 29908360
[TBL] [Abstract][Full Text] [Related]
4. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Battat R; Duijvestein M; Guizzetti L; Choudhary D; Boland BS; Dulai PS; Parker CE; Nguyen TM; Singh S; Vande Casteele N; Pai RK; Feagan BG; Sandborn WJ; Jairath V
Am J Gastroenterol; 2019 May; 114(5):733-745. PubMed ID: 30694863
[TBL] [Abstract][Full Text] [Related]
5. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
Chande N; McDonald JW; Macdonald JK
Cochrane Database Syst Rev; 2008 Apr; (2):CD006774. PubMed ID: 18425969
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
7. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
Ma C; Guizzetti L; Panaccione R; Fedorak RN; Pai RK; Parker CE; Nguyen TM; Khanna R; Vande Casteele N; D'Haens G; Sandborn WJ; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2018 Jun; 47(12):1578-1596. PubMed ID: 29696670
[TBL] [Abstract][Full Text] [Related]
9. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
Jairath V; Zou G; Parker CE; Macdonald JK; Mosli MH; Khanna R; Shackelton LM; Vandervoort MK; AlAmeel T; Al Beshir M; AlMadi M; Al-Taweel T; Atkinson NS; Biswas S; Chapman TP; Dulai PS; Glaire MA; Hoekman D; Koutsoumpas A; Minas E; Samaan MA; Travis S; D'Haens G; Levesque BG; Sandborn WJ; Feagan BG
J Crohns Colitis; 2016 May; 10(5):607-18. PubMed ID: 26746169
[TBL] [Abstract][Full Text] [Related]
11. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.
Ma C; Guizzetti L; Cipriano LE; Parker CE; Nguyen TM; Gregor JC; Chande N; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2019 Feb; 49(4):364-374. PubMed ID: 30569460
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Zhao X; Li N; Ren Y; Ma T; Wang C; Wang J; You S
PLoS One; 2016; 11(8):e0160500. PubMed ID: 27501314
[TBL] [Abstract][Full Text] [Related]
15. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
16. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Yoon H; Jangi S; Dulai PS; Boland BS; Prokop LJ; Jairath V; Feagan BG; Sandborn WJ; Singh S
Gastroenterology; 2020 Oct; 159(4):1262-1275.e7. PubMed ID: 32585306
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis.
Su C; Lewis JD; Goldberg B; Brensinger C; Lichtenstein GR
Gastroenterology; 2007 Feb; 132(2):516-26. PubMed ID: 17258720
[TBL] [Abstract][Full Text] [Related]
18. Type I interferons for induction of remission in ulcerative colitis.
Seow CH; Benchimol EI; Griffiths AM; Steinhart AH
Cochrane Database Syst Rev; 2008 Jul; (3):CD006790. PubMed ID: 18646167
[TBL] [Abstract][Full Text] [Related]
19. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD004115. PubMed ID: 20091560
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis.
Mohammed Vashist N; Samaan M; Mosli MH; Parker CE; MacDonald JK; Nelson SA; Zou GY; Feagan BG; Khanna R; Jairath V
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011450. PubMed ID: 29338066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
